Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line - Immunotherapy

- No Prior Therapy With PD-1/PD-L1
  - LUN0085
    - Phase II
    - Pembrolizumab in Metastatic Non-Squamous NSCLC
    - Examining Circulating Tumor DNA Levels
    - PI: Neal, Stanford
  - LUN0093
    - Phase II
    - NKTR-214 + Nivolumab in Select Locally Advanced or Metastatic Solid Tumor Malignancies
    - PI: Neal, Nektar

- On anti PD-1/ anti PD-L1 with response, stable disease or modest progression
  - LUN0088
    - Phase II
    - Radical-Dose RT with Anti-PD-1/ Anti-PD-L1 Immunotherapy in Non-Small Cell Lung Cancer
    - PI: Gensheimer Stanford
  - ECOGS1400
    - Phase II/III
    - Biomarker in Second Line Therapy of Squamous Cell Lung Cancer (Screening Step)
    - PI: Wakelee ECOG-ACRIN

- Failed Therapy PD-L1
  - LUN0107
    - Phase Ib/II
    - Grapiprant +/- Pembrolizumab in Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
    - PI: Wakelee Aryls Therapeutics
  - VAR0155
    - Phase 1b Atezolizumab Raltansine (BAY 94-9363) in Mesothelin Expressing Advanced/Recurrent Malignancies
    - PI: Padda, S
    - Bayer Healthcare

KEY
- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold